Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 32236 | 111 | 26.4 | 27% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 1294 | 8163 | FOOD AND DRUG LAW JOURNAL//GENERIC SUBSTITUTION//DIRECT TO CONSUMER ADVERTISING |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | BIOCHEMICAL ENGINEERING SCIENCE | Author keyword | 1 | 50% | 1% | 1 |
| 2 | IF I CLERSE | Address | 1 | 50% | 1% | 1 |
| 3 | UVB | Address | 1 | 50% | 1% | 1 |
| 4 | CROSS BORDER INTEGRATION | Author keyword | 0 | 33% | 1% | 1 |
| 5 | ORGANIZATIONAL POLICIES AND PRACTICES | Author keyword | 0 | 17% | 1% | 1 |
| 6 | BIOTECHNOLOGY DRUG EVALUATION | Author keyword | 0 | 100% | 1% | 1 |
| 7 | BIOTECHNOLOGY INVESTMENT | Author keyword | 0 | 100% | 1% | 1 |
| 8 | CULTURE OF CONSERVATION | Author keyword | 0 | 100% | 1% | 1 |
| 9 | DIFFUSION OF NEW TECHNOLOGY | Author keyword | 0 | 100% | 1% | 1 |
| 10 | DRUG UTILIZATION STRATEGIES | Author keyword | 0 | 100% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | METIAMIDE | 0 | 20% | 1% | 1 |
| 2 | FUT8 | 0 | 17% | 1% | 1 |
| 3 | HIGH TECHNOLOGY INDUSTRIES | 0 | 17% | 1% | 1 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
|---|---|---|---|---|
| Should scientific innovation be managed? | 2002 | 8 | 5 | 100% |
| Regulating transgenic plants in India - Biosafety, plant variety protection and beyond | 1999 | 1 | 1 | 100% |
| Innovation deficit revisited: reflections on the productivity of pharmaceutical R&D | 1998 | 22 | 2 | 50% |
| Australian biotechnology and bioscience based industry | 2000 | 0 | 2 | 100% |
| Passion versus fear as the emotion driving scientists | 1998 | 1 | 1 | 100% |
| Pharmaceutical firms and the transition to biotechnology: A study in strategic innovation | 1998 | 52 | 29 | 17% |
| Accelerating drug discovery: creating the right environment | 1997 | 2 | 5 | 60% |
| Strategic choices facing the pharmaceutical industry: A case for innovation | 1997 | 21 | 5 | 20% |
| The myth of the biotech revolution: An assessment of technological, clinical and organisational change | 2007 | 53 | 41 | 5% |
| The development of biochemical engineering science in Europe | 1997 | 3 | 10 | 20% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | IF I CLERSE | 1 | 50% | 0.9% | 1 |
| 2 | UVB | 1 | 50% | 0.9% | 1 |
| 3 | EUROPE MIDDLE E AFRICA | 0 | 100% | 0.9% | 1 |
| 4 | GLYC CELLULAR MOL MED ODONTOL | 0 | 100% | 0.9% | 1 |
| 5 | UNIT ENTREPRENEURSHIP | 0 | 100% | 0.9% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000169287 | THEORY OF ORGANISM//ARTIFICIAL CREATU//GUZEL SA AR TASARIM FAK |
| 2 | 0.0000145311 | PROGRAM LIFE SCI ETH POLICY//MCLAUGHLIN ROTMAN GLOBAL HLTH//ESRC INNOGEN |
| 3 | 0.0000130602 | BIC GRANADA//HERBAL NANOPARTICLES//RAJAH MUTHAIAH MED HOSP |
| 4 | 0.0000098374 | THE SHKODRA LAKE//ECOTECHNOLOGY//ECOLOGICAL ENGINEERING |
| 5 | 0.0000096588 | ADVOCACY ADVERTISING//DECIS MAKING STUDIES//DISCRETIONARY NARRATIVE DISCLOSURES |
| 6 | 0.0000091035 | ACADEMIC ENTREPRENEURSHIP//JOURNAL OF TECHNOLOGY TRANSFER//RESEARCH POLICY |
| 7 | 0.0000088990 | DEP AGR CHEM//ADHESION BETWEEN SPHERES//FRACTURE OF COLLOIDS |
| 8 | 0.0000076432 | CLINICAL TRIAL RISK//CONTINUOUS IMPROVEMENT//STRATEGIE IND |
| 9 | 0.0000073488 | HYBRID SCIENCE//MICRO POLICY//SOFTWARE PRODUCTS AND SERVICES |
| 10 | 0.0000072849 | MATERNITY BENEFIT//NEO CONTINGENCY//PEDAG EDUC PSYCHOL |